International Journal of Emerging Research in Applied Medical Sciences (IJERAMS)

Artificial Intelligence Across the Oncology Continuum: From Prevention to Survivorship

Dr. Nisha Verma[1], Dr. Rohan Desai[2], Mrs. Priya Kulkarni[3], Dr. Vivek Sharma[4], Mr. Akash Patil[5]

[1]Professor Department of Pharmaceutics, East Valley Institute of Pharmaceutical Sciences, Jaipur, India nisha.vrm82@gmail.com
[2]Associate Professor Department of Pharmaceutical Chemistry, East Valley Institute of Pharmaceutical Sciences, Jaipur, India rohands1991@gmail.com
[3]Assistant Professor Department of Pharmacy Practice, East Valley Institute of Pharmaceutical Sciences, Jaipur, India pkulkarni.47@gmail.com
[4]Professor Department of Pharmacology, East Valley Institute of Pharmaceutical Sciences, Jaipur, Indiadrvivek.sharma86@gmail.com
[5]Associate Professor Department of Pharmacognosy, East Valley Institute of Pharmaceutical Sciences, Jaipur, India akashpatil519@gmail.com

ABSTRACT

Artificial intelligence (AI) is transforming cancer care by supporting decision-making across every stage of the oncology continuum, from primary prevention and early detection to diagnosis, treatment selection, survivorship, and palliative care. Rapid advances in machine learning, deep learning, natural language processing, multimodal foundation models, and generative AI have enabled the analysis of complex biomedical data derived from medical imaging, digital pathology, genomics, electronic health records, wearable sensors, and patient-reported outcomes. These computational technologies facilitate individualized risk prediction, improve screening efficiency, optimize therapeutic planning, and enable continuous patient monitoring throughout the cancer journey. AI-driven systems are increasingly integrated into clinical workflows for radiology, pathology, molecular oncology, precision medicine, radiation therapy, surgical planning, and supportive care, thereby enhancing both clinical efficiency and patient outcomes.[1] Nevertheless, significant challenges remain regarding data quality, algorithmic bias, explainability, interoperability, cybersecurity, ethical governance, regulatory approval, and equitable implementation across diverse healthcare settings.[2] This review discusses the evolving role of artificial intelligence throughout the oncology continuum, emphasizing its applications in cancer prevention, early detection, diagnosis, precision medicine, and treatment planning while highlighting future opportunities for responsible clinical adoption.

Keywords: *Artificial intelligence, Precision oncology, Cancer prevention, Early detection, Machine learning, Deep learning, Digital pathology, Radiomics, Precision medicine, Oncology continuum.*

Article History
Received: 10 December 2025; **Accepted:** 18 December 2025; **Published:** 28 December 2025

Citation
Verma N., (2025). Artificial Intelligence Across the Oncology Continuum: From Prevention to Survivorship. *International Journal of Emerging Research in Applied Medical Sciences (IJERAMS), 1(5), 10-17.*
DOI: https://doi.org/10.65477/2026.v.1i.5.02

1. Introduction

Cancer remains one of the leading causes of mortality worldwide despite substantial advances in molecular biology, targeted therapies, immunotherapy, and precision medicine. The biological diversity of tumors, coupled with interpatient variability in genetics, environmental exposures, lifestyle factors, and immune responses, makes cancer management highly complex. Traditional treatment strategies based largely on tumor histology and anatomical staging often fail to account for individual biological differences, contributing to variable treatment responses and clinical outcomes.[3]

Simultaneously, modern oncology generates enormous amounts of heterogeneous data, including radiological images, pathology slides, genomic sequencing, transcriptomics, proteomics, laboratory investigations, electronic health records, wearable sensor outputs, and

e-ISSN: 3108-2599

real-world patient-reported outcomes. The volume and complexity of these datasets frequently exceed the capacity of conventional statistical approaches and routine clinical interpretation, creating opportunities for artificial intelligence to improve clinical decision-making.[4]

Artificial intelligence encompasses a broad collection of computational techniques capable of learning patterns from complex datasets and generating predictions that support clinical care. Machine learning algorithms identify statistical relationships among variables, while deep learning models automatically extract hierarchical representations from high-dimensional biomedical information. More recently, multimodal foundation models and generative AI have demonstrated remarkable capabilities in integrating imaging, molecular, pathological, and clinical information into comprehensive patient-specific representations.[5]

Rather than functioning only as diagnostic tools, AI technologies now support virtually every stage of the oncology continuum. From identifying individuals at increased cancer risk to optimizing long-term survivorship care, AI is increasingly enabling proactive, personalized, and data-driven cancer management. This review explores the expanding role of artificial intelligence across the oncology continuum, beginning with cancer prevention, screening, diagnosis, and precision treatment planning.

2. Evolution of Artificial Intelligence in Oncology

The application of artificial intelligence in medicine has evolved rapidly over the past several decades. Early computational systems relied primarily on rule-based expert systems that reproduced predefined clinical guidelines but lacked the ability to learn from new information. As larger healthcare datasets became available, machine learning algorithms emerged as powerful tools capable of identifying complex statistical associations that were difficult for traditional methods to recognize.[6]

The development of deep learning revolutionized oncology by enabling automated analysis of high-dimensional biomedical data. Convolutional neural networks achieved expert-level performance in interpreting radiological images and pathology slides, while recurrent neural networks facilitated longitudinal analysis of clinical records and treatment histories. More recently, transformer-based architectures have significantly improved the integration of multimodal biomedical data by simultaneously analyzing images, genomic profiles, pathology reports, and electronic health records.[7]

The widespread adoption of cloud computing, high-performance graphical processing units, electronic health records, and large-scale biomedical databases has further accelerated AI development. Today, artificial intelligence functions not merely as an analytical tool but as an intelligent clinical assistant capable of supporting multidisciplinary oncology teams throughout diagnosis, treatment, and follow-up.[8]

3. Artificial Intelligence Across the Oncology Continuum

The oncology continuum encompasses every stage of cancer care, beginning with disease prevention and extending through screening, diagnosis, treatment, survivorship, and end-of-life care. Artificial intelligence contributes uniquely at each stage by integrating diverse clinical data and generating individualized recommendations that improve healthcare delivery.

Unlike conventional approaches that focus on isolated clinical events, AI supports continuous learning throughout the patient's healthcare journey. As new clinical information becomes available, predictive models continuously refine their recommendations, allowing healthcare providers to adapt prevention strategies, treatment plans, and follow-up protocols according to evolving patient needs.[9]

This continuum-based approach represents a major paradigm shift from reactive healthcare toward predictive and preventive oncology.

4. Artificial Intelligence in Cancer Prevention

Cancer prevention remains one of the most effective strategies for reducing cancer-related morbidity and mortality. Artificial intelligence contributes to prevention by identifying individuals at elevated cancer risk long before clinical disease develops.

Machine learning algorithms analyze demographic characteristics, family history, environmental exposures, lifestyle behaviors, occupational hazards, genetic susceptibility, and medical history to generate individualized cancer risk estimates. These predictive models enable clinicians to recommend personalized preventive interventions, including smoking cessation, dietary modification, physical activity, vaccination, and genetic counseling.[10]

Population-level AI systems further support public health initiatives by identifying geographic regions with increased cancer incidence, monitoring environmental carcinogen exposure, and evaluating the effectiveness of prevention programs. Natural language processing also facilitates automated extraction of cancer risk factors from electronic health records, enabling healthcare systems to identify high-risk individuals who may benefit from earlier intervention.[11]

As genomic sequencing becomes increasingly accessible, AI-driven polygenic risk models are expected to further improve individualized cancer prevention strategies by integrating inherited genetic susceptibility with environmental and lifestyle factors.

5. Artificial Intelligence in Cancer Screening and Early Detection

Early detection substantially improves survival for many malignancies by identifying tumors before metastatic spread occurs. Artificial intelligence has emerged as an important tool for enhancing both the accuracy and efficiency of cancer screening programs.

Deep learning algorithms have demonstrated remarkable performance in mammographic breast cancer screening by detecting subtle imaging abnormalities that may be overlooked during routine interpretation. Similar AI systems have improved lung cancer detection on low-dose computed tomography, colorectal cancer screening through automated colonoscopy image analysis, cervical cancer detection using digital cytology, and skin cancer diagnosis through dermoscopic image classification.[12]

Beyond image interpretation, AI optimizes screening strategies by estimating individualized screening intervals according to patient-specific risk profiles. Rather than applying uniform population-based recommendations, predictive algorithms identify individuals who may benefit from earlier or more frequent screening while reducing unnecessary investigations among lower-risk populations.[13]

Integration of imaging findings with laboratory biomarkers, family history, genomic information, and lifestyle characteristics further enhances screening accuracy and minimizes false-positive examinations, improving both clinical outcomes and healthcare resource utilization.

6. Artificial Intelligence in Diagnostic Radiology

Medical imaging remains central to oncology diagnosis, staging, treatment planning, and disease monitoring. Artificial intelligence has transformed radiology by enabling rapid, reproducible, and highly accurate interpretation of complex imaging datasets.

Deep learning models automatically detect tumors, segment anatomical structures, quantify lesion volume, and classify imaging phenotypes associated with malignancy. These algorithms improve diagnostic consistency while reducing observer variability among radiologists.[14]

Radiomics has significantly expanded the clinical value of medical imaging by extracting hundreds of quantitative features describing tumor shape, texture, vascularity, and spatial heterogeneity. Machine learning models combine these imaging biomarkers with clinical and molecular information to predict tumor aggressiveness, treatment response, recurrence risk, and survival outcomes.[15]

Longitudinal imaging analysis further enables continuous assessment of therapeutic response. AI systems compare sequential imaging studies to detect subtle anatomical or functional changes that may indicate treatment success or emerging resistance before conventional clinical assessment becomes apparent.

7. Artificial Intelligence in Digital Pathology

Pathology remains the definitive standard for cancer diagnosis. The digitization of histopathological slides has enabled artificial intelligence to substantially improve diagnostic accuracy, reproducibility, and workflow efficiency.

Whole-slide imaging generates gigapixel digital pathology images containing millions of cellular structures. Deep learning algorithms analyze these images to identify tumor subtype, histological grade, mitotic activity, lymphovascular invasion, necrosis, stromal remodeling, and immune infiltration with remarkable precision.[16]

Transformer-based computational pathology models recognize complex spatial relationships among malignant cells, stromal components, and immune cells that may be difficult to quantify manually. These quantitative pathological features improve prognostic prediction while supporting personalized therapeutic decision-making.[17]

Recent advances have also enabled AI systems to infer clinically relevant molecular biomarkers—including microsatellite instability, HER2 amplification, EGFR mutations, and PD-L1 expression—directly from routine histopathological images, potentially reducing dependence on costly molecular testing.[18]

8. Artificial Intelligence and Molecular Oncology

Precision oncology increasingly depends on comprehensive molecular characterization of individual tumors. High-throughput sequencing technologies generate enormous genomic, transcriptomic, proteomic, and epigenomic datasets that require sophisticated computational analysis.

Artificial intelligence integrates molecular information with clinical and pathological variables to identify driver mutations, classify molecular subtypes, predict therapeutic sensitivity, and estimate prognosis. Machine learning algorithms recognize complex interactions among genes, signaling pathways, and regulatory networks that cannot easily be identified using conventional statistical approaches.[19]

AI also supports interpretation of variants of uncertain significance by comparing newly identified mutations with previously characterized genomic databases. This capability accelerates precision medicine while improving consistency across molecular pathology laboratories.

As multi-omics technologies continue to evolve, AI-driven molecular analysis is expected to become increasingly central to individualized cancer diagnosis and therapeutic selection.[20]

9. Multimodal Artificial Intelligence for Precision Oncology

One of the greatest strengths of modern artificial intelligence lies in its ability to integrate diverse biomedical information into unified computational models. Rather than analyzing imaging, pathology, genomics, or clinical data independently, multimodal AI combines these complementary sources to generate comprehensive patient-specific representations.

Transformer architectures and multimodal foundation models simultaneously process radiological images, pathology slides, genomic profiles, laboratory investigations, clinical documentation, and longitudinal treatment histories. Self-attention mechanisms identify meaningful biological relationships across these heterogeneous datasets, improving prediction accuracy compared with single-modality models.[21]

Such integrated computational approaches support individualized diagnosis, prognostic estimation, treatment selection, and outcome prediction while reducing uncertainty associated with isolated data interpretation.

10. Artificial Intelligence in Personalized Treatment Planning

Following diagnosis, selecting the optimal treatment strategy represents one of the most important decisions in oncology. Artificial intelligence assists clinicians by integrating clinical variables, tumor biology, molecular alterations, imaging findings, and prior treatment outcomes into individualized predictive models.

Machine learning algorithms estimate therapeutic response, recurrence probability, progression-free survival, treatment toxicity, and overall survival under multiple treatment scenarios. Physicians can compare chemotherapy regimens, targeted therapies, immunotherapy combinations, radiation strategies, and surgical options using evidence-based computational predictions tailored to each patient's unique disease characteristics.[22]

Clinical decision-support systems powered by AI further improve multidisciplinary collaboration by presenting individualized risk estimates, treatment recommendations, and supporting evidence through intuitive visualization platforms. Importantly, these systems complement rather than replace physician expertise, preserving clinician oversight while enhancing evidence-based decision-making.

11. Artificial Intelligence in Surgical Oncology

Surgical resection remains the primary curative treatment for many solid malignancies. Artificial intelligence is increasingly supporting surgeons throughout the perioperative pathway by improving preoperative planning, intraoperative guidance, and postoperative risk assessment. Advanced machine learning algorithms analyze radiological imaging, three-dimensional anatomical reconstructions, and patient-specific clinical variables to estimate tumor extent, vascular involvement, lymph node status, and anticipated surgical complexity.[23]

Three-dimensional visualization platforms powered by AI enable surgeons to simulate multiple operative approaches before entering the operating room. These systems improve understanding of anatomical relationships, facilitate organ-preserving procedures, and assist in achieving adequate oncological margins while minimizing injury to surrounding healthy tissues. Integration with robotic surgical systems and computer-assisted navigation further enhances surgical precision by providing real-time anatomical guidance during complex procedures.

Artificial intelligence also contributes to postoperative management by predicting complications such as surgical site infections, anastomotic leakage, prolonged hospitalization, and readmission. Early identification of high-risk patients enables timely preventive interventions, improving recovery and reducing healthcare costs.

12. Artificial Intelligence in Radiation Oncology

Radiation therapy plays a central role in the management of numerous malignancies. Successful treatment depends upon accurate target delineation, individualized dose optimization, and protection of surrounding normal tissues. Artificial intelligence has substantially improved each stage of the radiotherapy workflow.

Deep learning algorithms automatically segment tumors and organs at risk on computed tomography and magnetic resonance imaging, reducing the time required for treatment planning while improving consistency among radiation oncologists. Machine learning models further estimate tumor radiosensitivity and predict the likelihood of treatment-related toxicities based on imaging biomarkers, genomic information, and clinical characteristics.[24]

Adaptive radiation therapy has emerged as one of the most promising AI applications. Sequential imaging acquired throughout treatment enables continuous assessment of tumor shrinkage and anatomical changes. Artificial intelligence updates treatment plans in response to these changes, allowing radiation delivery to remain optimized despite evolving patient anatomy. This adaptive approach improves tumor control while reducing unnecessary radiation exposure to adjacent healthy organs.

13. Artificial Intelligence in Immuno-Oncology

Immunotherapy has transformed cancer treatment by harnessing the immune system to eliminate malignant cells. However, considerable variability exists in patient

e-ISSN: 3108-2599

response, making prediction of therapeutic benefit a major clinical challenge.

Artificial intelligence integrates genomic alterations, tumor mutational burden, immune-cell composition, digital pathology, radiological imaging, circulating biomarkers, and clinical variables to estimate the probability of response to immune checkpoint inhibitors and other immunotherapeutic strategies.[25]

Computational pathology algorithms quantify tumor-infiltrating lymphocytes, immune checkpoint expression, stromal architecture, and spatial interactions between malignant and immune cells. These measurements provide important biological insights that complement molecular testing and support personalized immunotherapy selection.

As single-cell sequencing and spatial transcriptomics continue to advance, AI is expected to generate increasingly comprehensive models of tumor-immune interactions, facilitating individualized immunotherapeutic strategies while minimizing immune-related adverse events.

14. Artificial Intelligence in Drug Discovery and Precision Therapeutics

Development of anticancer drugs remains a lengthy, expensive, and resource-intensive process. Artificial intelligence has begun transforming pharmaceutical research by accelerating target identification, molecular design, drug screening, and prediction of therapeutic efficacy.

Machine learning algorithms analyze enormous biological datasets to identify previously unrecognized molecular pathways involved in carcinogenesis. Generative AI further accelerates drug discovery by designing novel molecular structures with favorable pharmacological characteristics before laboratory synthesis.

Artificial intelligence also predicts pharmacokinetics, toxicity profiles, resistance mechanisms, and potential drug-drug interactions using integrated molecular and clinical datasets. These computational approaches reduce experimental costs while increasing the probability of successful clinical translation.

Within precision oncology, AI assists clinicians in selecting targeted therapies by integrating genomic sequencing, transcriptomics, proteomics, and real-world treatment outcomes to match individual patients with therapies most likely to produce durable clinical benefit.[26]

15. Artificial Intelligence in Survivorship Care

The number of long-term cancer survivors continues to increase owing to advances in early detection and treatment. Consequently, survivorship care has become an increasingly important component of comprehensive oncology practice.

Artificial intelligence supports survivorship by continuously evaluating treatment history, genetic susceptibility, comorbidities, lifestyle factors, laboratory investigations, wearable sensor data, and patient-reported outcomes to estimate long-term health risks. Predictive algorithms identify individuals at increased risk of cardiovascular disease, endocrine dysfunction, neurocognitive impairment, osteoporosis, secondary malignancies, chronic fatigue, and psychosocial complications resulting from cancer therapy.[27]

Wearable technologies and mobile health applications enable continuous remote monitoring of physiological parameters such as heart rate, physical activity, sleep quality, and oxygen saturation. Integration of these digital biomarkers with electronic health records allows AI systems to detect early signs of recurrence, treatment-related toxicity, or declining functional status, facilitating timely clinical intervention.

Personalized survivorship plans generated through AI may optimize follow-up schedules, preventive care, rehabilitation strategies, and supportive interventions while reducing unnecessary healthcare utilization.

16. Artificial Intelligence in Supportive and Palliative Care

Comprehensive oncology extends beyond tumor-directed treatment to include symptom management, psychosocial support, and quality-of-life improvement. Artificial intelligence increasingly contributes to supportive and palliative care by enabling proactive identification of patient needs.

Natural language processing extracts symptom information from clinical documentation and patient-reported narratives, while predictive models estimate the likelihood of severe pain, malnutrition, depression, fatigue, nausea, hospitalization, and emergency department utilization.

AI-powered conversational systems and digital health platforms facilitate symptom reporting between clinic visits, allowing healthcare providers to intervene before complications become severe. Predictive algorithms also support individualized pain management and optimize supportive therapies according to patient-specific clinical characteristics.

These technologies have the potential to improve quality of life while enhancing communication between patients, caregivers, and multidisciplinary oncology teams.[28]

17. Ethical, Regulatory, and Implementation Challenges

Despite remarkable technological progress, successful implementation of artificial intelligence in oncology requires careful consideration of several scientific, ethical, and regulatory challenges.

High-quality AI models depend upon diverse, representative datasets. Incomplete, biased, or poorly annotated training data may produce inequitable predictions that disproportionately affect underrepresented populations. Ensuring fairness therefore requires inclusive datasets and rigorous external validation across multiple healthcare systems.

Model transparency represents another critical consideration. Explainable AI techniques—including saliency maps, attention visualization, feature attribution methods, and counterfactual explanations—help clinicians understand the reasoning underlying algorithmic predictions, thereby improving trust and facilitating responsible clinical adoption.

Cybersecurity, patient privacy, interoperability, regulatory approval, and continuous post-deployment monitoring remain essential for maintaining safe and reliable AI-assisted healthcare systems. Collaborative governance involving clinicians, data scientists, policymakers, regulatory agencies, and patients will be fundamental for responsible implementation.[29]

18. Future Perspectives

Artificial intelligence is expected to become increasingly integrated throughout every stage of the oncology continuum. Multimodal foundation models capable of simultaneously interpreting imaging, pathology, genomics, laboratory investigations, clinical documentation, and wearable sensor data are likely to support increasingly comprehensive clinical decision-making.

Generative AI will continue to accelerate drug discovery, biomarker identification, medical education, and clinical documentation. Reinforcement learning may optimize adaptive treatment strategies by continuously learning from real-world patient outcomes, while federated learning will facilitate collaborative model development without compromising patient privacy.

Future oncology ecosystems will likely integrate artificial intelligence with robotics, digital pathology, molecular diagnostics, precision imaging, remote monitoring, and clinical decision-support systems into unified platforms that enable continuous personalized care from prevention through survivorship.

Large prospective clinical studies, standardized validation frameworks, transparent regulatory oversight, and equitable implementation strategies will be essential for translating these technological advances into routine clinical practice.[30]

19. Discussion

Artificial intelligence is fundamentally reshaping modern oncology by supporting clinical decision-making across the entire cancer continuum. Rather than functioning as isolated diagnostic tools, contemporary AI systems integrate diverse biomedical information to provide individualized recommendations throughout prevention, screening, diagnosis, treatment, survivorship, and supportive care.

Applications in radiology, pathology, molecular oncology, immunotherapy, surgical planning, radiation therapy, and survivorship illustrate the remarkable breadth of AI's clinical impact. These technologies have demonstrated substantial potential to improve diagnostic accuracy, optimize therapeutic selection, reduce unnecessary interventions, enhance workflow efficiency, and support precision medicine.

Nevertheless, artificial intelligence should complement—not replace—clinical expertise. Human oversight remains essential for interpreting predictions, incorporating patient preferences, addressing ethical considerations, and ensuring compassionate, patient-centered care. Successful implementation will depend upon multidisciplinary collaboration, continuous validation, transparent governance, and equitable access across diverse healthcare settings.

20. Conclusion

Artificial intelligence is transforming every stage of the oncology continuum, from cancer prevention and early detection to diagnosis, precision treatment, survivorship, and supportive care. By integrating medical imaging, digital pathology, molecular profiling, clinical records, wearable technologies, and patient-reported outcomes, AI enables increasingly personalized, evidence-based, and adaptive cancer management.

Rapid advances in machine learning, deep learning, multimodal foundation models, natural language processing, and generative artificial intelligence are expected to further enhance clinical decision-making, therapeutic optimization, and long-term patient monitoring. As these technologies mature and undergo rigorous clinical validation, they will become increasingly embedded within routine oncology practice.

Although important challenges remain regarding data quality, explainability, privacy, fairness, interoperability, regulation, and implementation, continued collaboration among clinicians, researchers, engineers, industry, and policymakers will accelerate responsible adoption. Ultimately, artificial intelligence has the potential to transform oncology from a predominantly reactive specialty into a predictive, preventive, personalized, and continuously learning discipline that improves outcomes and quality of life for patients across the entire cancer journey.

References

1. Meric-Bernstam, F. et al. (2023) 'Enhancing Precision Oncology Through Multimodal Data Integration', Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4
3. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7
4. Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.
5. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5
6. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5
7. Dr. Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38
8. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14
9. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12
10. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18
11. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7
12. Dr. Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31
13. Dr. Ohminwsi Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325, DOI: https://doi.org/10.46121/pspc.52.4.14
14. Dr. Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21

15. Dr. Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16
16. Dr. Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33
17. Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.
18. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.
19. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.
20. Dr. Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
21. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
22. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
23. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
24. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
25. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
26. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
27. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
28. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
29. Boehm, K.M. et al. (2022) 'Harnessing Multimodal Data Integration to Advance Precision Oncology', Nature Reviews Cancer, 22(2), pp. 114–126.
30. Wei, L. et al. (2023) 'Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration', British Journal of Radiology, 96(1150), Article 20230211.